Prescription Drug Prices Record Sharpest Decline in More Than 60 Years Under Trump Administration Policies

Prescription drug prices in the United States fell 3.1 percent over the 12 months ending in July, the steepest year-over-year drop since March 1963, according to Bureau of Labor Statistics data. The broader category of medicinal drugs declined 2.7 percent over the same period. Prices dropped at an annualized rate of 6.6 percent during the most recent six months, the sharpest six-month decline on record.

The White House pointed to the figures as clear evidence that President Donald Trump’s drug pricing agenda is delivering results for American patients. Administration officials highlighted a combination of most-favored-nation pricing agreements with major pharmaceutical manufacturers, the TrumpRx direct-to-consumer platform, and expanded efforts to lower costs under Medicare. Trump has long argued that Americans have effectively subsidized lower drug prices in other countries and has made reducing those costs a central promise of his second term.

The TrumpRx platform, launched earlier this year, allows patients to access discounted prices on a growing list of medications, including popular GLP-1 drugs used for weight loss and diabetes management such as Wegovy and Zepbound. Starting doses and certain strengths have been offered at substantially reduced monthly rates compared with previous list prices that often exceeded $1,000. The platform has expanded repeatedly, adding hundreds of brand-name and generic drugs and reaching coverage for a large share of commonly filled prescriptions. Officials have reported hundreds of millions of dollars in patient savings through the most-favored-nation deals since the program began.

In parallel, a Medicare pilot program for GLP-1 medications, launched in July, secured agreements with manufacturers to provide the drugs to eligible beneficiaries at a net monthly price of approximately $245, with low out-of-pocket costs for many seniors. The administration has also continued and expanded Medicare’s authority to negotiate prices for selected high-cost drugs, building on the framework first established in 2022, with the initial round of negotiated prices taking effect in 2026 and additional selections under way.

These measures coincide with the historic decline in the official price index for prescription drugs at a time when broader medical service costs have continued to rise and overall consumer prices have remained elevated in other categories. White House officials described the drop as unique in modern presidential history and a direct outcome of aggressive pressure on manufacturers to align U.S. prices more closely with those charged in other developed nations.

The data offer tangible relief for patients, particularly those relying on branded specialty medications and seniors enrolled in Medicare. While multiple factors, including increased availability of generics, contribute to price movements in any given period, the administration maintains that its combination of direct purchasing tools, negotiated discounts, and most-favored-nation pressure has driven the scale of the recent reductions. Further expansions of the TrumpRx formulary and additional Medicare negotiations are expected as the policies continue to take hold.